Current Perspectives on Analytical Method Validation of Empagliflozin: A Comprehensive Review
by Dr. Uday A. Deokate, Govind Kokani, Lalit Bhoye, Muskan Mulla, Vaishnavi Punase, Vijay Lokhande, Vinod Kulkarni
Published: May 6, 2026 • DOI: 10.51244/IJRSI.2026.1304000126
Abstract
Empagliflozin is an oral hypoglycemic drug belonging to the class of SGLT2 inhibitors. It acts on transporters in the proximal tubules of the kidneys to reduce blood glucose by promoting glucose excretion in the urine. This review examines various analytical method development strategies for Empagliflozin, with a focus on Quality by Design (QbD) approaches.